Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SPY 230

Next Previous
Drug Profile

SPY 230

Alternative Names: PR-025; SPY-230; SPY002-SPY003; SPY002/SPY003

Latest Information Update: 24 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Paragon Therapeutics
  • Developer Paragon Therapeutics; Spyre Therapeutics
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Interleukin 23 inhibitors; Tumour necrosis factor ligand superfamily member 15 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ulcerative colitis
  • Preclinical Inflammatory bowel diseases

Most Recent Events

  • 13 Apr 2026 Efficacy and adverse events data from the phase II SKYLINE trial in Ulcerative colitis released by Spyre Therapeutics
  • 27 May 2025 Phase-II clinical trials in Ulcerative colitis in Slovakia, Romania, Japan, Italy, India, Hungary, Greece, Jordan, France, Bulgaria, Belgium (IV) (NCT07012395)
  • 27 May 2025 Phase-II clinical trials in Ulcerative colitis in Slovakia, Romania, Japan, Italy, India, Hungary, Greece, Jordan, France, Bulgaria, Belgium (SC) (NCT07012395)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top